There was no association of treatment or AD with trastuzumab (AHR, 1.00; 95% CI 0.82-1.23), taxane (AHR, 1.08; 95% CI, 0.90-1.30), endocrine therapy (including those treated only with tamoxifen [AHR, 0.92; 95% CI, 0.78-1.09], aromatase inhibitor [AHR, 1.04; 95% CI, 0.90-1.20]), or combined tamoxifen and aromatase inhibitors (AHR, 1.09; 95% CI, 0.73-1.62) (Table 3). The gene discussed is CYP19A1; the disease is Alzheimer disease.